Allergan deal with tribe could kill off IPR: Bryson

A US judge has said Allergan’s controversial patent licensing deal with a Native American tribe could spell the end for the inter partes review (IPR).

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Mohawk tribe and Allergan seek en banc hearing in Restasis case

21 August 2018 Allergan and the Saint Regis Mohawk Tribe asked the full US Court of Appeals for the Federal Circuit on Friday to review an earlier decision that rejected use of tribal sovereign immunity in the inter partes review.

Americas

Mylan opposes Allergan’s attempted withdrawal from Restasis IPRs

19 January 2018 Generics company Mylan Pharmaceuticals has resisted Allergan’s attempt to withdraw itself from a series of inter partes reviews (IPRs) relating to patents covering dry-eye medication Restasis (cyclosporine ophthalmic emulsion).

Americas

Miami police officers sue Allergan over tribe patent deal

30 November 2017 A group of Miami police officers has filed a competition lawsuit on behalf of “potentially millions” of consumers over Allergan’s $13.75 million patent deal with the Saint Regis Mohawk Tribe.

More features

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

Allergan deal with tribe could kill off IPR: Bryson

More on this story

Editor's picks

Editor's picks

More features